trending Market Intelligence /marketintelligence/en/news-insights/trending/1hksjr_6lbiqkn-kfxczja2 content esgSubNav
In This List

US FDA issues warning to Bayer over drug manufacturing violations

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


US FDA issues warning to Bayer over drug manufacturing violations

The U.S. Food and Drug Administration issued a warning letter to Bayer AG over violations at its drug manufacturing facility in Leverkusen, Germany, Reuters reported.

The German pharmaceutical company is addressing the concerns raised by the regulator.

Bayer is expecting temporary supply limitations that will affect its blood pressure drug Adalat, blood thinner Aspirin Cardio, antibiotic Avelox and potency drug Levitra.

The company will quantify the impact in its upcoming 2018 guidance on Feb. 28.